论文部分内容阅读
作者用常位(肝内)及异位(右腋皮下)移植人肝癌动物瘤株(LTNM_4)裸小鼠模型,以阿霉素(ADR)、米托蒽醌(DHAQ)作比较,对肝靶向制剂米托蒽醌毫微球(DHAQ-PBCA-NS)的抗肝癌效果进行了研究。结果表明:ADR、DHAQ和DHAQ-PBCA-NS对常位移植人肝癌的抑瘤率分别为60.07％、67.49％和99.44％。对异位移植人肝癌的抑瘤率分别为80.03％、86.18％和92.90％。用抗增殖细胞核抗原(PCNA)单克隆抗体PC_(10),采用ABPAP法显示细胞增殖活性,ADR、DHAQ和DHAQ-PBCA-NS的PCNA计数分别为85.5±12.7％、76.0±13.4％和31.0±23.0％。经t检验显示,DHAQ抗肝癌效果与ADR相当,而DHAQ-PBCA-NS抗常位移植人肝癌的效果明显优于ADR和DHAQ,具有应用研究前景。
The authors used a nude mouse model of human liver cancer animal tumor (LTNM_4) in orthotopic (intrahepatic) and ectopic (right subcondylar subcutaneous) transplantation, compared with adriamycin (ADR), mitoxantrone (DHAQ), and liver The anti-liver cancer effect of targeted mitoxantrone nanospheres (DHAQ-PBCA-NS) was studied. The results showed that the tumor inhibitory rates of ADR, DHAQ and DHAQ-PBCA-NS on orthotopic liver transplantation were 60.07%, 67.49% and 99.44%, respectively. The tumor-inhibiting rates of heterotopic transplanted human liver cancer were 80.03%, 86.18%, and 92.90%, respectively. Cell proliferative activity was measured by ABPAP method using anti-proliferating cell nuclear antigen (PCNA) monoclonal antibody PC_(10). PCNA counts of ADR, DHAQ, and DHAQ-PBCA-NS were 85.5±12.7%, 76.0±13.4%, and 31.0±, respectively. 23.0%. The t-test showed that DHAQ had anti-liver cancer effect comparable to that of ADR, while DHAQ-PBCA-NS had better anti-cancer effect than human ADR and DHAQ. It has application prospects.